From the Philadelphia PCF Center of Excellence to a VISN-Level Cancer Center
As we reflect on the incredible accomplishments of the Hematology/Oncology Research Team at the Philadelphia PCF Center of Excellence, we want to extend a heartfelt thank you to the generous supporters of the Prostate Cancer Foundation (PCF), whose valuable contributions have played a crucial role in our progress toward becoming a VISN-level cancer center. This transformation will significantly enhance our ability to serve Veterans who are affected by prostate cancer.
Since PCF began supporting us in 2019, we have made remarkable strides. We’ve built our oncology team from the ground up and secured multimillion-dollar funding from the VA, with a goal of achieving self-sustainability within the next five years.
Advancing Precision Medicine
In 2024, our dedicated team, led by Dr. Kyle Robinson, Dr. Yu-Ning Wong, and Dr. Kara Maxwell, made significant headway in advancing precision medicine for Veterans. Our efforts have been focused on three main areas: genetic testing, clinical trials, and biobanking.
Expanding Genetic Testing
This year, we tested 202 patients at the Philadelphia VA for inherited genetic changes and 284 for changes that occurred in their tumors. We have successfully implemented these initiatives across several VA Medical Centers, ensuring that more Veterans have access to essential genetic information.
Clinical Trials Enrollment
In 2024, our center enrolled an additional 12 patients into the VA PATCH program, bringing our total to 20. We also enrolled 9 patients in SWOG cooperative group trials. Our team works diligently to identify Veterans who may benefit from these trials, ensuring they have opportunities for new and innovative treatments.
Biobanking Efforts
Under Dr. Maxwell's leadership, our MAPP-SEQ biobanking study has advanced substantially. In 2024, we enrolled 127 patients and collected samples from 96 of them, which helps us gain a deeper understanding of prostate cancer and its treatment.
Collaborative Partnerships
Our collaborations with VISN4 partners in Wilmington, DE, Wilkes-Barre, Coatesville, and Lebanon, PA, continue to strengthen our services. Drs. Maxwell and Aiello have expanded genetic testing across these locations, and our team participates in the monthly Molecular Oncology Tumor Board, where we discuss important patient cases and research findings.
Mentorship and Training
We are also committed to nurturing the next generation of cancer researchers. Dr. Kara Maxwell is mentoring five students and one postdoctoral researcher, ensuring that the future of prostate cancer research remains bright.
Looking Ahead to 2025
As we move into 2025, we are excited about our collaboration with the POPCaP network to enhance precision medicine initiatives. Additionally, we are pleased to announce the launch of the VA-funded VISN4 Cancer Clinical Research Center, which will improve access to genetic testing, teleoncology services, and clinical trial opportunities for rural and underserved Veterans.
We extend our deepest gratitude to our PCF donors for your continued support. Your generosity is vital in our mission to improve cancer care for Veterans and ensure ongoing progress in prostate cancer research and treatment.